Compare Northrop Grumman Corporation (NOC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Twist Bioscience Corp — how do they compare? Northrop Grumman Corporation trades at $514.98 (market cap $74.42B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Northrop Grumman Corporation is far larger — about 13.7× Twist Bioscience Corp's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NOC | TWST | |
|---|---|---|
Market Cap | $74.42B | $5.45B |
Sector | Industrials | Health |
52-Week High | $768.02 | $102.88 |
52-Week Low | $496.02 | $24.16 |
Enterprise Value | $88.65B | $5.37B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $512.29, down 1.78% amid a bearish technical signal despite strong Q2 2026 earnings that beat estimates and a record $105 billion backlog. The stock faces margin pressures but maintains solid fundamentals with a P/E of 16.43 and ROE of 28.51%. Recent news highlights raised 2026 guidance driven by robust defense demand, though the stock's decline reflects investor concerns over cost challenges.
The outlook is mixed: bullish fundamentals and analyst consensus ($655 price target) support long-term growth, but near-term risks include execution on margin targets and technical bearishness. Investment appeal hinges on defense budget tailwinds offsetting operational headwinds.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
